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Abstract
Background
Globally, few studies compare progress toward the Joint United Nations Program on HIV/
AIDS (UNAIDS) Fast-Track targets among migrant populations. Fast-Track targets are
aligned to the HIV diagnosis and care cascade and entail achieving 90-90-90 (90% of peo-
ple living with HIV [PLHIV] diagnosed, 90% of those diagnosed on treatment, and 90% of
those on treatment with viral suppression [VS]) by 2020 and 95-95-95 by 2030. We com-
pared cascades between migrant and nonmigrant populations in Australia.
Methods and findings
We conducted a serial cross-sectional survey for HIV diagnosis and care cascades using
modelling estimates for proportions diagnosed combined with a clinical database for propor-
tions on treatment and VS between 2013–2017. We estimated the number of PLHIV and
number diagnosed using New South Wales (NSW) and Victorian (VIC) data from the Aus-
tralian National HIV Registry. Cascades were stratified by migration status, sex, HIV expo-
sure, and eligibility for subsidised healthcare in Australia (reciprocal healthcare agreement
[RHCA]). We found that in 2017, 17,760 PLHIV were estimated in NSW and VIC, and 90%
of them were males. In total, 90% of estimated PLHIV were diagnosed. Of the 9,391 who
were diagnosed and retained in care, most (85%; n = 8,015) were males. We excluded 38%
of PLHIV with missing data for country of birth, and 41% (n = 2,408) of eligible retained
PLHIV were migrants. Most migrants were from Southeast Asia (SEA; 28%), northern
Europe (12%), and eastern Asia (11%). Most of the migrants and nonmigrants were males
(72% and 83%, respectively). We found that among those retained in care, 90% were on
antiretroviral therapy (ART), and 95% of those on ART had VS (i.e., 90-90-95). Migrants
had larger gaps in their HIV diagnosis and care cascade (85-85-93) compared with
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nonmigrants (94-90-96). Similarly, there were larger gaps among migrants reporting male-
to-male HIV exposure (84-83-93) compared with nonmigrants reporting male-to-male HIV
exposure (96-92-96). Large gaps were also found among migrants from SEA (72-87-93)
and sub-Saharan Africa (SSA; 89-93-91). Migrants from countries ineligible for RHCA had
lower cascade estimates (83-85-92) than RHCA-eligible migrants (96-86-95). Trends in the
HIV diagnosis and care cascades improved over time (2013 and 2017). However, there was
no significant increase in ART coverage among migrant females (incidence rate ratio [IRR]:
1.03; 95% CI 0.99–1.08; p = 0.154), nonmigrant females (IRR: 1.01; 95% CI 0.95–1.07; p =
0.71), and migrants from SEA (IRR: 1.03; 95% CI 0.99–1.07; p = 0.06) and SSA (IRR: 1.03;
95% CI 0.99–1.08; p = 0.11). Additionally, there was no significant increase in VS among
migrants reporting male-to-male HIV exposure (IRR: 1.02; 95% CI 0.99–1.04; p = 0.08).
The major limitation of our study was a high proportion of individuals missing data for country
of birth, thereby limiting migrant status categorisation. Additionally, we used a cross-sec-
tional instead of a longitudinal study design to develop the cascades and used the number
retained as opposed to using all individuals diagnosed to calculate the proportions on ART.
Conclusions
HIV diagnosis and care cascades improved overall between 2013 and 2017 in NSW and
VIC. Cascades for migrants had larger gaps compared with nonmigrants, particularly
among key migrant populations. Tracking subpopulation cascades enables gaps to be iden-
tified and addressed early to facilitate achievement of Fast-Track targets.
Author summary
Why was this study done?
• Reaching the end of the AIDS epidemic by achieving the Joint United Nations Program
on HIV/AIDS (UNAIDS) Fast-Track targets requires tracking progress across all popu-
lation groups.
• Fast-Track targets entails reaching 90-90-90 (90% of people living with HIV diagnosed,
90% of those diagnosed on treatment, and 90% of those on treatment with viral suppres-
sion) by 2020 and 95-95-95 by 2030.
• Migrants often face barriers to healthcare access because of their migration status, socio-
cultural influence, financial constraints, and stigma.
• There are limited data on HIV diagnosis, care, and treatment among migrants, which is
required in order to streamline the HIV response.
What did the researchers do and find?
• We developed HIV diagnosis and care cascades for migrants and nonmigrants in Aus-
tralia between 2013 and 2017.
• The overall cascade was high in New South Wales and Victoria (i.e., 90-90-95).
HIV diagnosis and care cascade for migrants in Australia
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• Migrants had inferior cascades (85-85-93) compared with nonmigrants (94-90-96),
including migrants reporting male-to-male HIV exposure (84-83-93) compared with
nonmigrants (96-92-96).
• Between 2013 and 2017, subpopulation cascades improved, except for females, irrespec-
tive of migration status and migrants from Southeast Asia.
What do these findings mean?
• In our study, although the overall HIV diagnosis and care cascades improved over time
in Australia, migrants lagged behind.
• Failure to develop subpopulation cascades may lead to gaps going unnoticed.
• To address gaps, there is need for streamlined strategies, especially among migrant pop-
ulations, to ensure timely HIV testing and linkage to care.
Introduction
Reaching the end of the AIDS epidemic by achieving the Joint United Nations Program on
HIV/AIDS (UNAIDS) Fast-Track targets set for 2020 and 2030 [1,2] requires tracking progress
across all populations at risk and living with HIV. Fast-Track targets entail 90% of people liv-
ing with HIV (PLHIV) are diagnosed, 90% of those diagnosed receive sustained antiretroviral
therapy (ART), and 90% of those on ART achieve viral suppression (VS) (i.e., 90-90-90) by
2020 and scaling up to 95-95-95 by 2030. Reaching the Fast-Track targets by 2030 is projected
to lead to at least 90% reduction of HIV incidence compared with 2010 [2].
Although progress is being made globally, significant gaps still exist as we work toward the
UNAIDS target; importantly, new HIV infections are not decreasing fast enough [3]. The inci-
dence reduction goal is more likely to be achieved if HIV prevention strategies are strength-
ened [4] and if the potential pools of high HIV viral loads are eliminated. In 2017, 75% of
PLHIV globally were diagnosed, 79% of those diagnosed were on ART, and 81% of those were
on ART with VS (i.e., 59% on ART and 48% virally suppressed of all PLHIV). However, there
were 1.8 million new infections, which was higher than anticipated [5]. It is thought the
higher-than-expected incidence may be due to gaps in key populations receiving care, includ-
ing adolescent girls, young women, and migrants [5].
Migrants comprise a considerable proportion of PLHIV globally, but there are limited data
on diagnosis and treatment rates in this important population. Although the UNAIDS Global
AIDS update report provides HIV diagnosis and care cascade data at global, regional, and
country levels, the onus is upon countries to track subpopulation cascades. In Australia, 29%
of the population was born overseas, and 33% of the 27,545 estimated to be living with HIV in
2017 were born overseas—mainly Southeast Asia (SEA), sub-Saharan Africa (SSA), and the
Americas [6,7]. In 2017, 89% of PLHIV in Australia were aware of their HIV status, 87% were
on ART, and of those, 95% were virally suppressed [6]. Although the number of new infections
decreased in Australia, particularly among men who have sex with men (MSM), new HIV
infections among migrants increased [6]. Migrants were also more likely to present with a late
HIV diagnosis than citizens [6, 8,9]. These differences raise concerns that migrants are being
HIV diagnosis and care cascade for migrants in Australia
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‘left behind’, highlighting the need to focus on this group if Australia is to achieve the Fast-
Track targets.
Migrants face barriers to healthcare access because of their migration status, sociocultural
influence, financial constraints, and stigma [5,10]. Limited access to healthcare for migrants
has been highlighted in many European countries, including Spain, Portugal, and Ireland,
with the need to consider equity and equality [11,12]. In Asia, migrant workers had limited
access to HIV testing, especially when undocumented [13]. In Australia, citizens and perma-
nent residents have subsidised general healthcare access, including HIV care services, through
the national health insurance scheme (Medicare). Additionally, temporary residents from
countries with a reciprocal healthcare agreement (RHCA) with Australia (i.e., Belgium, Fin-
land, Italy, Malta, Netherlands, New Zealand, Norway, Ireland, Slovenia, Sweden, and United
Kingdom) are eligible for subsidised access through Medicare. However, migrants outside of
these categories are not eligible for Medicare, although some may access HIV care and treat-
ment through compassionate access programmes or private health insurance [6,8]. When
reporting HIV diagnosis and care cascades, it is important to provide subpopulation cascades
to track progress toward Fast-Track targets and ensure no one is left behind.
In this study, we developed the HIV diagnosis and care cascades for migrants (stratified
according to migrant populations) and compared them to the cascade of nonmigrants (2013–
2017) to explore gaps and opportunities to inform the national and state HIV response
strategies.
Methods
We developed HIV diagnosis and care cascades using modelling estimates for proportions
diagnosed combined with a clinical database for proportions on treatment and virally sup-
pressed between 2013–2017 following a prespecified analysis plan (S1 Text) and the STROBE
checklist for observational studies (S1 STROBE Checklist).
Study population and data sources
To estimate the number of people living with diagnosed HIV (PLDHIV) we primarily used
New South Wales (NSW) and Victorian (VIC) data from the Australian National HIV Regis-
try. Additional data from the Australian Bureau of Statistics (ABS) and follow-up studies of
people recently diagnosed with HIV were used to inform population movement estimates
[14]. The number of undiagnosed PLHIV was estimated using back-projection modelling
from CD4+ count at diagnosis [15].
In Australia, all new HIV diagnoses must be reported by laboratories and/or doctors to
state and territory health departments, who submit these data to the National HIV Registry
[6,16]. State and territory authorities use this information to analyse and report surveillance
data to the National HIV Registry, which is maintained by the Kirby Institute at the University
of New South Wales (UNSW Sydney), on behalf of the Australian Government Department of
Health [17]. HIV diagnoses among immigrants to Australia are added to the national HIV reg-
istry if they have lived in Australia for at least 3 months and intend to reside in the notifying
state/territory, including among people previously diagnosed overseas [6]. HIV notifications
in the registry are accompanied by a range of information with varying levels of completeness.
Data from the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of
Sexually Transmissible Infections and Blood Borne Viruses (ACCESS) database were used to
determine the number retained in care and calculate proportions on treatment and VS [18].
ACCESS is a national sexual health surveillance network that collects and collates routine dei-
dentified data from over 120 sexual health clinics, general practice clinics, community health
HIV diagnosis and care cascade for migrants in Australia
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services, hospitals, and pathology laboratories across Australia, and records are anonymously
linked between sites [18]. The ACCESS network collects demographic, testing, diagnosis, and
treatment data to monitor the sexual health of high-risk populations. Compared with other
states, NSW and VIC have the highest coverage in the ACCESS database, and they comprise
the highest proportion of PLHIV and migrants in Australia [6,7].
ACCESS data have been used previously to report on HIV treatment outcomes mostly in NSW
and VIC [14,19]. The ACCESS database has a high coverage of treatment and viral load data for
PLHIV in NSW and VIC. A total of 7,998 and 9,727 PLHIV were captured in the ACCESS net-
work in 2016 and 2017, respectively, across seven general practice clinics, two hospitals, and 33
sexual health clinics and linked. ACCESS captures 53%–57% of the estimated PLHIV (diagnosed
and nondiagnosed) and 59%–63% of the estimated diagnosed PLHIV in NSW and VIC [14,20].
Data collection
Data collected in ACCESS include date of visit, country of birth, area of residence, sex, self-
reported HIV transmission category, ART status, and HIV viral load results. Country of birth
is self-reported to the diagnosing clinician; we used this variable to classify individuals as
migrants (born outside Australia) or nonmigrants (born in Australia). Based on country of
birth, individuals were also grouped into region of birth based on the ABS classification [7].
Country of birth was also used to determine whether the individual was from a country eligible
for RHCA with Australia [21]. Individuals missing country of birth and sex were compared
separately. We excluded trans and gender-diverse persons because of their small numbers (6
in 2013 and 18 in 2017).
Cascade variables. We produced estimates for the HIV diagnosis and care cascade for the
overall population and by migration status, sex, male-to-male HIV exposure, migrants from
SEA and SSA, and migrants from countries with RHCA with Australia.
The first two steps of the cascades (the number of PLHIV and the number of diagnosed
PLHIV) were estimated using previously developed methods applied to data from Australia’s
National HIV Registry, with numbers rounded to the nearest 10. Full details of the registry
and calculations are available from the HIV, viral hepatitis, and sexually transmissible infec-
tions in Australia Annual Surveillance Report, 2018 [6]; previous publications [14,22]; and an
online repository containing all the code used in the calculations [23].
To estimate the number of diagnosed PLHIV for each stratification, complete notification
data for several key variables were required. To address the missing data in the HIV Registry
and to obtain the complete notification data required for our analysis, we used predictive
mean matching univariate imputation using known notification data to the end of 2017 from
the six notification variables: year of diagnosis (100% complete), age at diagnosis (99.4% com-
plete), sex and gender (99.5% complete), country and region of birth (69.6% complete), and
exposure category/likely route of HIV transmission (86.6% complete) for each jurisdiction
(100% complete). From this imputation process, we produced 10 sets of notifications with
complete information for each of the six variables to account for statistical uncertainty. This
imputation was conducted using the MICE software package in the R statistical software pro-
gram [24,25]. Using the 10 imputed notifications sets, we estimated the number of PLHIV and
the number diagnosed in NSW and VIC to 31 December 2017 for each region of birth, with an
estimated upper and lower bound for each, as described in the following two subsections.
PLDHIV (first 90)
From each imputed set of notifications, we determined the annual number of PLDHIV for
each subpopulation in NSW and VIC separately by summing all notifications meeting the
HIV diagnosis and care cascade for migrants in Australia
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appropriate criteria and then subtracting duplicates, estimated deaths, overseas emigrants, and
net interstate departures. The range for PLDHIV for each set was estimated by multiplying the
appropriate lower and upper bounds for the number of deaths (estimated using the 95% CI of
the death rate), emigrants, and interstate arrivals and departures. Our overall estimate for
PLDHIV was then obtained by summing the mean NSW and VIC estimates for each popula-
tion from the 10 imputed notification sets with a range between the minimum and maximum
values from the sets.
Number of undiagnosed PLHIV. To estimate the proportion of PLHIV who were undi-
agnosed for each population, we applied the European Centre for Disease Prevention and
Control (ECDC) HIV Modelling Tool and added this to the estimated number of PLDHIV
[15]. The ECDC tool is a multistate back-calculation model using HIV notification data and
estimates for the rate of CD4+ T-cell decline to fit diagnosis rates over time, which produces
an estimate and range of the undiagnosed population and the percentage undiagnosed. The
range in PLHIV was obtained by applying the lower estimate for proportion undiagnosed to
the lower limit for PLDHIV and, conversely, for the upper bound.
First 90 ¼
Number of estimated PLDHIV
Number of estimated PLHIV
Number of PLDHIV retained in care
We used the ACCESS database to identify the number retained in care, defined as PLDHIV
with a consult/HIV viral load test (VL)/on ART in that year. Using the ACCESS database for
those retained in care, we calculated the proportions on ART and virally suppressed to com-
plete the HIV diagnosis and care cascade.
Proportion of PLDHIV retained in care on ART (second 90)
We used ART status as captured in the ACCESS database for PLDHIV receiving a three-drug
regimen for treatment in that year. We queried the database for all HIV-positive individuals
with ART documentation per year. We used this proportion to estimate the second 90 instead
of the traditional proportion of diagnosed who are on ART.
Second 90 ¼
Number of PLDHIV retained in care on ART in ACCESS database
Number of PLDHIV retained in care in ACCESS database
Proportion of PLDHIV retained in care on ART with VS (third 90)
To calculate the number of PLDHIV retained in care on ART with VS, we used the last VL in
the year for patients on ART recorded in the ACCESS database irrespective of ART duration.
VS was defined as VL< 200 copies per millilitre.
Third 90 ¼
Number of PLDHIV retained in care on ART with VS in ACCESS database
Number of PLDHIV retained in care on ART in ACCESS database with a VL result
Statistical methods
To build the HIV testing and treatment cascade for each year, proportions were calculated for
the first 90, second 90, and third 90 based on the UNAIDS 90-90-90 targets (as described pre-
viously). The cascades were developed using a cross-sectional approach applied annually.
We developed the overall cascade and subpopulation cascades by sex, migration status,
male-to-male HIV exposure, migrants born in SEA, migrants born in SSA, and RHCA status.
HIV diagnosis and care cascade for migrants in Australia
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We estimated the overall ART coverage (first 90 � second 90) and VS (first 90 � second 90 �
third 90) among all estimated PLHIV and compared it with targets of 81% and 73% by 2020,
respectively, by calculating the appropriate proportion and the 95% CI for the proportions [2].
Individuals missing country of birth (could not be classified as migrants or nonmigrants)
or sex in the ACCESS database were tracked separately for ART coverage and VS.
Poisson regression was used to describe annual trends of cascade proportions over time
(2013–2017) using incidence rate ratio (IRR), 95% CI, and a p-value. Data modelled in the
Poisson regression were checked for overdispersion. Data analysis was conducted using Stata
IC 14 (Stata Corp, College Station, TX), with the significance level set at p< 0.05. We present
the cascades for 2017 in detail and used all cascades (2013–2017) to explore trends.
The study was approved by The Alfred Ethics Committee (Project No. 248/17) and Monash
University Human Ethics Committee (Project No. 11221).
Results
HIV diagnosis and care cascade in 2017
In 2017, there were an estimated 17,760 PLHIV in NSW and VIC; 90% were males, and 90%
(95% CI 90%–91%) had been diagnosed (PLDHIV). Of the 9,391 retained in care in the
ACCESS database in 2017, most (85%, n = 8,015) were males. Migration status could not be
determined for 38% of PLHIV because of missing country of birth. Of those with a country of
birth entry (n = 5,817), 41% (n = 2,408) were migrants. Most migrants were from SEA (28%),
northern Europe (12%), and eastern Asia (11%). Most of the migrants and nonmigrants were
males (72% and 83%, respectively). Of the retained migrants, 90% (95% CI 90%–91%) were on
ART, and 95% (95% CI 95%–96%) of those on ART had VS. Overall, we estimated that 81%
and 77% of all estimated PLHIV were on ART and virally suppressed, respectively (Table 1).
Of the 38% of PLHIV missing country of birth in the ACCESS database, 94% (95% CI 94%–
95%) were on ART, and 96% (95% CI 95%–97%) on ART had VS. Of those missing sex (9%),
96% (95% CI 95%–98%) were on ART, and 96% (95% CI 95%–97%) on ART had VS. The rest
of the data used to develop the HIV care cascades and the estimated numerators and denomi-
nators for the cascade calculations are included in the Supporting information (S1 and S2
Tables).
Migrant subpopulations had larger gaps in the HIV diagnosis and care cascade estimates
compared with nonmigrants, as shown in Table 1. Among migrants estimated to be living
with HIV (37%; n = 6,570), 85% (95% CI 85%–86%) were diagnosed, and of those retained in
care, 85% (95% CI 84%–87%) were on ART, and 93% (95% CI 92%–94%) of those on ART
had VS. Among nonmigrants estimated to be living with HIV, 94% (95% CI 93%–94%) were
diagnosed, and of those retained in care, 90% (95% CI 89%–91%) were on ART, and 96%
(95% CI 95%–97%) had VS.
The estimated overall ART coverage was the highest among nonmigrants (88%), nonmi-
grant males (84%), migrants born in SSA (83%), and those eligible for RHCA (83%) and lowest
among nonmigrant females (63%). The estimated overall VS was >73% in migrants born in
SSA (75%), migrants with RHCA (74%), nonmigrant males (76%), and nonmigrants reporting
male-to-male HIV exposure (80%) (Table 1).
Migrants reporting male-to-male HIV exposure had lower cascade estimates (84-87-93)
compared with nonmigrants reporting similar exposure (96-92-96). Migrants born in SEA
also had lower cascade estimates (72-87-93) compared with those born in SSA (89-93-91).
Similarly, migrants from countries not eligible for RHCA had lower cascade estimates (83-85-
92) compared with those eligible (96-86-95). Females had lower cascade estimates irrespective
of whether they were migrants (87-79-90) or nonmigrants (92-70-88) (Table 1).
HIV diagnosis and care cascade for migrants in Australia
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HIV diagnosis and care cascade trends (2013–2017)
Between 2013–2017, the trend in the overall annual proportion diagnosed (first 90) in NSW
and VIC was stable (IRR: 1.00; 95% CI 0.99–1.01; p = 0.281), including among migrants (IRR:
1.01; 95% CI 0.99–1.02; p = 0.142), nonmigrants (IRR: 1.00; 95% CI 0.99–1.01; p = 0.71), and
other subpopulations (Table 2).
Fig 1 highlights the cascade trends of migrants compared with nonmigrants, and Fig 2 com-
pares male-to-male HIV exposures. The trend in the overall annual proportion on ART (sec-
ond 90) increased (IRR: 1.06; 95% CI 1.05–1.06; p< 0.001), including in migrants (IRR: 1.04;
95% CI 1.03–1.06; p< 0.001) and nonmigrants (IRR: 1.04; 95% CI 1.03–1.06; p< 0.001) (Fig
1). However, there was no increasing trend among migrant females (IRR: 1.03; 95% CI 0.99–
1.08; p = 0.154), nonmigrant females (IRR: 1.01; 95% CI 0.95–1.07; p = 0.707), migrants from
SEA (IRR: 1.03; 95% CI 0.99–1.07; p = 0.055), and migrants from SSA (IRR: 1.03; 95% CI
0.99–1.08; p = 0.108) (Table 2).
VS proportions were generally high over the years and were�90% in 2017 in all subpopula-
tions except nonmigrant females. There was an increasing trend in VS among all PLHIV (IRR:
1.02; 95% CI 1.01–1.03; p< 0.001). However, there was no increasing VS trend in migrants
reporting male-to-male HIV exposure (IRR: 1.02; 95% CI 0.99–1,04; p = 0.076) (Fig 2), female
migrants (IRR: 1.02; 95% CI 0.96–1.08; p = 0.584), migrants born from SEA (IRR: 1.03; 95% CI
0.99–1.06; p = 0.178), and migrants born from SSA (IRR: 1.01; 95% CI 0.96–1.06; p = 0.794)
(Table 2).
Table 1. HIV diagnosis and care cascades in New South Wales and Victoria (2017).
Variable First 90, % (95%
CI)
Second 90, % (95%
CI)
Third 90, % (95%
CI)
Estimated on ART of all
PLHIV�
Estimated viral suppression of all
PLHIV��
All PLHIV 90 (90–91)¥ 90 (90–91) 95 (95–96) ¥ 81£ 77£
Male 90 (90–91) ¥ 91 (90–91) 95 (95–96) ¥ 82£ 79£
Female 89 (87–90) 78 (74–81) 91 (87–94) 69 63
Migrants 85 (85–86) 85 (84–87) 93 (92–94) ¥ 73 67
Male 85 (84–86) 84 (83–86) 92 (91–94) ¥ 71 66
Female 87 (85–89) 79 (74–84) 90 (84–94) 69 62
Nonmigrant 94 (93–94) ¥ 90 (89–91) 96 (94–96) ¥ 85£ 81£
Male 93 (93–94) ¥ 90 (88–91) 96 (95–97) ¥ 84£ 80£
Female 92 (90–94) ¥ 70 (63–77) 88 (80–94) 64 57
Male-to-male HIV exposure 91 (90–91) ¥ 90 (89–91) 96 (95–96) ¥ 82£ 79£
Migrant 84 (83–85) 87 (85–88) 93 (91–94) ¥ 73 68
Nonmigrant 96 (95–96) ¥ 92 (90–93) 96 (95–97) ¥ 88£ 85£
Migrants born in SEA 72 (70–74) 87 (84–90) 93 (90–95) ¥ 63 58
Migrants born in SSA 89 (87–91) 93 (89–95) 91 (87–95) 83£ 75£
Migrants eligible for RHCA 96 (95–97) 86 (82–88) 95 (92–97) ¥ 83£ 78£
Migrants not eligible for
RHCA
83 (82–84) 85 (84–87) 92 (91–94) ¥ 71 65
Missing country of birth n/a 94 (94–95) 96 (95–97) n/a n/a
Missing sex n/a 96 (95–98) 96 (95–97) n/a n/a
�The target for estimated proportion on ART of all PLHIV in 2020 is 81%, and estimates were calculated per subpopulation living with HIV.
��The target for estimated proportion with viral suppression of all PLHIV is 73% in 2020, and estimates were calculated per subpopulation living with HIV.
¥90-90-90 target met.
£Overall target met.
Abbreviations: ART, antiretroviral therapy; PLHIV, people living with HIV; RHCA, reciprocal healthcare agreement; SEA, Southeast Asia; SSA, sub-Saharan Africa
https://doi.org/10.1371/journal.pmed.1003044.t001
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Table 2. HIV diagnosis and care cascade trends for New South Wales and Victoria (2013–2017).
Variable 2013 (%) 2014 (%) 2015 (%) 2016 (%) 2017 (%) IRR (95% CI) p-Value
Diagnosed (first 90) 89 90 90 90 90 1.00 (0.99–1.01) 0.281
Male 89 90 90 90 90 1.00 (0.99–1.01) 0.444
Female 87 87 88 88 89 1.01 (0.99–1.02) 0.482
Migrants 83 84 85 85 85 1.01 (0.99–1.02) 0.142
Male 83 84 84 84 85 1.01 (0.99–1.01) 0.286
Female 85 85 86 86 87 1.01 (0.98–1.03) 0.569
Nonmigrant 93 93 94 94 94 1.00 (0.99–1.01) 0.710
Male 93 93 93 93 93 1.00 (0.99–1.01) 0.878
Female 94 93 93 93 92 0.99 (0.97–1.02) 0.798
Male-to-male HIV exposure 90 90 91 91 91 1.00 (0.99–1.01) 0.393
Migrant 83 84 84 84 84 1.00 (0.99–1.01) 0.691
Nonmigrant 95 95 95 95 96 1.00 (0.99–1.01) 0.483
Born in SEA 70 70 71 72 72 1.01 (0.99–1.03) 0.369
Born in SSA 83 85 87 88 89 1.02 (0.99–1.04) 0.137
RHCA eligible 94 95 95 96 96 1.01 (0.99–1.02) 0.534
RHCA not eligible 80 81 81 82 83 1.01 (0.99–1.02) 0.099
On ART (second 90) 72 74 77 86 90 1.06 (1.05–1.06) <0.001
Male 70 73 76 86 91 1.06 (1.05–1.07) <0.001
Female 66 67 71 76 78 1.04 (1.01–1.08) 0.012
Missing sex 89 90 93 95 96 1.02 (0.99–1.04) 0.122
Missing country of birth 70 73 75 91 94 1.08 (1.07–1.09) <0.001
Migrant 71 72 78 81 85 1.04 (1.03–1.06) <0.001
Male 67 69 75 79 84 1.05 (1.03–1.07) <0.001
Female 69 69 75 77 79 1.03 (0.99–1.08) 0.154
Nonmigrant 74 76 79 84 90 1.04 (1.03–1.05) <0.001
Male 72 74 77 83 90 1.04 (1.03–1.05) <0.001
Female 67 68 71 71 70 1.01 (0.95–1.07) 0.707
Male-to-male HIV exposure 69 72 76 87 90 1.07 (1.06–1.08) <0.001
Migrant 67 70 77 81 87 1.06 (1.04–1.08) <0.001
Nonmigrant 73 75 79 85 92 1.05 (1.04–1.06) <0.001
Born in SEA 76 77 83 83 87 1.03 (0.99–1.07) 0.055
Born in SSA 80 83 88 90 93 1.03 (0.99–1.08) 0.108
RHCA eligible 70 73 77 80 86 1.04 (1.01–1.07) 0.016
RHCA not eligible 71 72 78 81 85 1.04 (1.02–1.06) <0.001
Viral suppression (third 90) 89 91 92 95 95 1.02 (1.01–1.03) <0.001
Male 89 91 92 95 95 1.02 (1.01–1.03) <0.001
Female 84 87 87 91 91 1.02 (0.97–1.06) 0.351
Missing sex 92 92 95 95 97 1.01 (0.99–1.04) 0.331
Missing country of birth 91 94 95 96 97 1.01 (0.99–1.03) 0.068
Migrants 87 89 90 93 93 1.02 (1.00–1.04) 0.046
Male 85 88 88 93 92 1.02 (1.00–1.04) 0.044
Female 85 88 86 91 90 1.02 (0.96–1.08) 0.584
Nonmigrant 87 89 92 94 96 1.02 (1.01–1.04) 0.001
Male 87 89 92 94 96 1.03 (1.01–1.04) 0.001
Female 83 85 86 92 88 1.02 (0.95–1.09) 0.609
Male-to-male HIV exposure 89 92 92 95 96 1.02 (1.01–1.03) <0.001
Migrant 87 88 88 93 93 1.02 (0.99–1.04) 0.076
Nonmigrant 87 90 92 95 96 1.02 (1.01–1.04) 0.002
Migrants born in SEA 83 90 87 92 93 1.03 (0.99–1.06) 0.178
Migrants born in SSA 88 91 92 92 91 1.01 (0.96–1.06) 0.794
Migrants eligible for RHCA 90 91 91 96 95 1.02 (0.98–1.05) 0.369
Migrants not eligible for RHCA 85 88 89 93 92 1.02 (0.99–1.04) 0.064
Abbreviations: ART, antiretroviral therapy; IRR, incidence rate ratio; RHCA, reciprocal healthcare agreement; SEA, Southeast Asia; SSA, sub-Saharan Africa
https://doi.org/10.1371/journal.pmed.1003044.t002
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Fig 1. HIV diagnosis and care cascades for all PLHIV, migrants, and nonmigrants in NSW and VIC (2013–2017). ART,
antiretroviral therapy; NSW, New South Wales; PLHIV, people living with HIV; VIC, Victoria; VS, viral suppression.
https://doi.org/10.1371/journal.pmed.1003044.g001
Fig 2. HIV diagnosis and care cascades for all male-to-male HIV exposure, migrants, and nonmigrants in NSW and VIC (2013–
2017). ART, antiretroviral therapy; NSW, New South Wales; VIC, Victoria; VS, viral suppression.
https://doi.org/10.1371/journal.pmed.1003044.g002
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Discussion
Our results suggest that although gaps in the overall HIV diagnosis and care cascade in NSW
and VIC decreased between 2013 and 2017, there were notable and sustained gaps in migrant
subpopulations. Overall, migrants had lower HIV diagnosis and retention across the HIV care
cascade than nonmigrants, especially the proportion diagnosed and on ART (first and second
90). Migrants reporting male-to-male HIV exposure, born in SEA and SSA, ineligible for sub-
sidised healthcare through RHCA, and who were female had lower HIV diagnosis and reten-
tion across the care cascade than nonmigrants. There was a particularly low proportion of
PLHIV born in SEA who were diagnosed (72% in 2017). As we approach 2020, the first Fast-
Track target year, we estimated that in 2017, 70% and 65% of migrants estimated to be living
with HIV in NSW and VIC were on ART and virally suppressed, respectively. This was lower
than 80% and 77%, respectively, in nonmigrants estimated to be living with HIV.
To the best of our knowledge, this is the first analysis that examined and compared HIV
diagnosis and the care cascade in migrants in Australia. In a survey of 55 European and Cen-
tral Asian countries, Brown and colleagues (2018) identified that only 41% produced cascades
for key and vulnerable populations, but there was wide variation between countries and no
subpopulation comparisons [26]. Our findings are consistent with other studies that identified
that mobile populations often face barriers to HIV testing and treatment access and often have
lower VS, suggesting that they have lower HIV diagnosis and retention in the care cascade
than citizens [26,27]. Italian researchers reported that migrants living with HIV had barriers to
initiating ART and a higher risk of virologic failure compared with nonmigrants [28]. In coun-
tries with concentrated epidemics, HIV diagnosis and care among MSM are often similar to
overall national cascades, but migrants often have lower treatment coverage and VS [26]. A
review by Tanser and colleagues (2015) also identified poorer HIV diagnosis and care cascades
among migrants and found that existing health system structures failed to properly account
for migrants who still present late and have poor retention [29]. In Australia, the incidence of
HIV in newly arrived Asian-born MSM was found to be higher than other subpopulations
[30]. Although Medicare ineligibility is a significant barrier, it is known that migrants are less
likely to be offered or less likely to initiate early ART despite having access [31,32].
Migrants are often more likely to have higher HIV prevalence, higher frequency of late HIV
diagnosis, and lower VS rates and to experience barriers to healthcare access than the general
population [29,33,34]. Studies in Australia have previously identified that migrants faced barri-
ers to HIV testing, including cost and eligibility for health services, low visibility or awareness
of HIV in Australia, HIV-related stigma, sociocultural and religious influences, and missed
opportunities for testing during general practitioner visits [10,35]. Our study found that
migrants from countries that are not eligible for RHCA had lower HIV diagnosis and care cas-
cades compared with those who are eligible. An additional layer of barriers includes legal status
of migrants. A study that compared documented and undocumented migrants in Italy found
that despite free access to ART, migrants still had difficulties in gaining optimal HIV care [34].
In contrast, other studies found that when healthcare cost barriers are removed for migrants
living with HIV, VS increases, thereby reducing risk of transmission [36,37]. Removing barri-
ers that migrants living with or at risk of HIV face is expected to improve health outcomes and
progress toward the UNAIDS Fast-Track targets.
The poorer cascade for Australian-born females is of particular concern. However, our analysis
did not explore differences between indigenous and nonindigenous Australians. Surveillance data
have shown that between 2013 and 2016, the rate of HIV notifications increased by 41% in the
indigenous population and remained 1.6 times higher compared with the nonindigenous popula-
tion in 2016 [6]. According to the surveillance data, a greater proportion of HIV notifications in
HIV diagnosis and care cascade for migrants in Australia
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003044 March 10, 2020 11 / 15
the indigenous population is attributed to heterosexual sex (21%) or injecting drug use (18%)
compared with the Australian-born nonindigenous population (18% and 3%, respectively). Fur-
ther comparisons between indigenous and nonindigenous Australian-born populations is war-
ranted to compare whether there are differences in HIV testing, treatment coverage, and VS.
Previous work by our group suggests that reaching the Fast-Track targets may not be
enough to achieve HIV incidence reduction, especially in countries like Australia with low
HIV prevalence [4]. Scaling up other HIV prevention strategies, such as HIV testing, preexpo-
sure and postexposure prophylaxis, and condom use, would be required. Realising the full pre-
vention and treatment benefits of the UNAIDS Fast-Track strategy will require reaching all
key and vulnerable subpopulations, including migrants [29]. This is particularly important at
this stage of the HIV epidemic response and with increasing levels of global migration [38].
Understanding the dynamics of HIV and migration can be complex because migrants can be
at risk of HIV infection before, during, and after migration. HIV prevention and treatment
programmes will need to take into consideration these dynamics with an inclusive approach.
Limitations of our study included a high proportion (38% in 2017) of individuals retained in
ACCESS database missing a country of birth entry. This impacted our ability to categorise
migrants or nonmigrants and migrant populations. However, we tracked ART coverage and VS
among those missing country of birth and found similar or higher proportions compared with
nonmigrants. We used a cross-sectional instead of a longitudinal approach to develop the cas-
cades of care because it was not feasible to link individuals diagnosed in the National HIV Reg-
istry to the clinical database. Hence, we used the proportion of individuals retained in care in
the clinical database who initiated ART to estimate the second 90 of the cascade. Another limi-
tation was that all patients on ART, irrespective of ART duration, were counted in the analysis,
including patients newly initiated on ART. This has the potential to overestimate the number
not virally suppressed. The generalizability of our work is reduced because it only included two
Australian states (NSW and VIC). However, these states have the highest proportion of PLHIV
and migrants [7] and are likely to be reasonably representative of the national picture. Finally,
the analysis considered country of birth as a proxy for migrant status and Medicare eligibility
and may have misclassified people born in other countries who were Australian citizens and
Medicare eligible. Additional data that can better classify migrants, including year of arrival,
years lived in Australia, and visa category, are needed. Follow-up modelling studies are required
to reveal the differences between migrants and nonmigrants in order to highlight additional
sociodemographic characteristics that may be used to design public health programmes.
Conclusion
Gaps in the overall HIV diagnosis and retention in the care cascade in NSW and VIC
decreased between 2013 and 2017. However, there were notable and sustained gaps in migrant
subpopulations. In particular, retention of migrants in the care cascade was lower compared
with nonmigrants. Notable low retention occurred in migrants reporting male-to-male HIV
exposure, migrants from SEA and SSA, migrants not eligible for subsidised healthcare access
in Australia, and females (migrants and nonmigrants). Migration is a global issue, with global
migration increasing. If the HIV response is to meet the Fast-Track HIV incidence reduction
target, it is important to monitor HIV diagnosis and the care cascades in all subpopulations to
ensure that no one is being left behind.
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